Dr. Emily Alice Strong Duym, MD

Dr. Duym practices at Methodist Southlake Medical Center in Southlake, Texas, part of Methodist Hospitals of Dallas.

Dr. Duym's NPI, 1225591134, was assigned on April 8, 2019. Dr. Duym holds Indiana license 01090024A.

Dr. Duym's primary practice is Methodist Southlake Medical Center, at 421 E State Highway 114, Southlake, TX 76092 in Tarrant County. The practice phone is (878) 654-4400. Dr. Duym also practices at Methodist Southlake Hospital, 8701 Broadway, Merrillville, IN 46410.

Dr. Duym's primary practice is Methodist Southlake Medical Center in Southlake, Texas, part of Methodist Hospitals of Dallas. Dr. Duym is also affiliated with Javon Bea Hospital-Riverside. The medical group on file is CEP America. Dmand AI also links Dr. Duym to 1 more hospital and 5 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Duym practices, 3 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Duym's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dmand AI has Dr. Duym's licenses on file in 3 states: Indiana, Illinois and Wisconsin.

CMS data shows 377 Medicare services from Dr. Duym across 4 procedure codes in 2024, for 266 Medicare patients. Medicare paid $36,933 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 266 Medicare patients who saw Dr. Duym in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 55% are also on Medicaid. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Duym's median patient age at 62, with 55% women.

In 2024, Dr. Duym wrote 217 Medicare Part D claims for 135 patients. 90% of them were for generic drugs. CMS names the drug for 113 of them, across 7 drugs with 11 or more claims each, at $1,452 in total drug cost. In 2023, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Duym for performance year 2024, reported as part of a group. Dr. Duym accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Duym from 1 drug or device company in 2023. Food and beverage make up the largest share, 100% of the total. Fisher & Paykel Healthcare Inc paid the most, $24.